← brief for 2026-11-03 · Slowing decline

Dose-Exposure-Response Analysis of Finerenone on Serum Potassium and Cardiovascular Outcomes Among Patients With Heart Failure: Insights From FINEARTS-HF.

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

This analysis comes from a large randomized trial of 6,001 people with heart failure. It looked at how the dose of a drug called finerenone affected heart and kidney outcomes. The study found that the drug's benefits were linked to the dose and how well it was absorbed. This is a large trial, so the evidence is strong.

Who did this work

Eissing T · Mc Causland FR · Vaduganathan M · Goulooze SC · Marostica E · Berkhout J · van den Berg P · Snelder N · Garmann D · Lippert J · Brinker M · Claggett BL

Source

Article · PubMed, the drug frontier · 2026 Nov 3
https://pubmed.ncbi.nlm.nih.gov/42977544/